Delgocitinib Cream Shows "Super Response" in Chronic Hand Eczema: Daily Dose

News
Article
Delgocitinib Cream Shows "Super Response" in Chronic Hand Eczema: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


On March 10, 2025, we reported on findings from a post hoc subgroup analysis of the DELTA 1 and DELTA 2 phase 3 clinical trials presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL.

The study

In the post hoc analysis, investigators reported on a subgroup analysis of 960 adults with moderate to severe chronic hand eczema (CHE) who were enrolled in the DELTA 1 and DELTA 2 phase 3 trials of delgocitinib. The analysis defined "super response" as one of three response levels to the treatment:

  • A deep response, defined as a Hand Eczema Symptom Diary (HESD) itch of 0 (clear) or 1 (almost clear); HESD pain 0 or 1, and/or a Dermatology Life Quality Index (DLQI) score of 0 or 1 at week 16.

  • A consistent response, defined as a ≥4 point reduction in HESD itch, HESD pain, or achievement of Hand Eczema Severity Index (HESCI)-75 at weeks 4, 8, 12, and 16.

  • A maintained response, defined as achieving an Investigator's Global Assessment (IGA)-CHE of 0 (clear) at week 16 and maintaining IGA-CHE 0 off treatment.

The findings

Results revealed a HESD itch of 0 or 1 for 30.0% of delgocitinib-treated participants vs 9.4% of those treated with vehicle; 35.2% vs 6.0% achieved HESD pain 0 or 1, and 33.3% vs 13.9% achieved a DLQI score of 0 or 1 at week 16 with delgocitinib and vehicle cream, respectively, reflecting a deep response to the treatment.

A greater proportion of participants receiving delgocitinib vs vehicle cream also achieved a consistent response: a 4-point or greater reduction from baseline in HESD itch (24.1% vs 6.6%) or pain (25.0% vs 9.0%) or at least 75% improvement on the HECSI-75 (27.3% vs. 8.1%). Among participants receiving delgocitinib cream who achieved an IGA-CHE score of 0 at Week 16, 32.9% maintained a score of 0 after 8 weeks and 15.7% after 16 weeks.

Author's comments

"It is so exciting to see such a strong response in a subgroup of patients treated with delgocitinib cream. The results across the various treatment metrics are promising and demonstrate the future potential that delgocitinib cream may have in offering a new treatment option for those living with this unique and burdensome disease."

Click here for more details.


Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Related Content
© 2025 MJH Life Sciences

All rights reserved.